Cytosorbents Corporation · NASDAQ:CTSO
Cytosorbents — Investor Presentation (February 2025)
30 slides from Cytosorbents's investor presentation, February 2025
Slide 1: Investor Presentation February 2025
NASDAQ: CTSO Investor Presentation February 2025 1 |
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents Medical, Inc and CytoSorbents Europe GmbH that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actu
Slide 3: CytoSorbents at a Glance
CytoSorbents at a Glance • Platform blood purification technology for removing toxins and harmful substances from the blood • High margin “razorblade” that is “plug and play” into existing hospital blood pumps • Two main products leveraging the underlying polymer technology o CytoSorb • Treatment of
Slide 4: The Power of the Bead
The Power of the Bead Hemocompatible, highly porous polymer bead platform technology that act like tiny sponges to remove harmful substances from blood by pore capture, adsorption, and concentration • Excellent removal of a broad range of substances from whole blood and plasma • Solid state porous p
Slide 5: Products are "Plug and Play" Compatible
Products are “Plug and Play” Compatible Compatible with Existing Blood Pump Infrastructure In Hospitals Today CytoSorbents PuriFi Pump Dialysis or CRRT Hemoperfusion (Continuous Renal Replacement Therapy) (Standalone Treatment) Launched Q2 2024 CytoSorbents launched its PuriFi pump, an easy-to-use h
Slide 6: Looks Like Dialysis, but Key Differences
Looks Like Dialysis, but Key Differences We are Expanding the Dimension of Blood Purification® by removing a broad range of toxins that dialysis does not remove well CytoSorb works like the liver Dialysis works like the kidney Large Molecules and Fat soluble substances Small Molecules and Water solu
Slide 7: The Opportunity of DrugSorb-ATR
The Opportunity of 7 | * The DrugSorb-ATR system is an investigational device that is not yet cleared/approved by FDA, Health Canada, or by any other Global Regulatory Agency and is not commercially available for sale
Slide 8: Large Unmet Need for Blood Thinner Reversal
Large Unmet Need for Blood Thinner Reversal Millions of people worldwide are on Anti-thrombotic blood thinners to reduce risk of heart attack and stroke Brilinta® (ticagrelor) Eliquis® (apixaban) Xarelto® (rivaroxaban) (AstraZeneca) (Pfizer, BMS) (Bayer, Jansenn/J&J) Acute Coronary Syndrome, Atrial
Slide 9: DrugSorb-ATR is an FDA Breakthrough Device
DrugSorb-ATR is an FDA Breakthrough Device • DrugSorb-ATR is an investigational device that uses an equivalent polymer technology to CytoSorb and installs easily into a cardiopulmonary bypass machine * • As whole blood is pumped through the cartridge, it is designed to remove free drug during surger
Slide 10: Brilinta and the Use Case for DrugSorb-ATR
Brilinta and the Use Case for ® 5 - 10% will need open heart surgery The ultimate goal of DrugSorb-ATR is to allow patients to get the critical surgery they need without X X XX X delay, while reducing or preventing 10 | bleeding complications
Slide 11: Cardiac Surgery and Bleeding Risk
Cardiac Surgery and Bleeding Risk Bleeding at baseline varies according to type of cardiothoracic surgery without the use of antithrombotic drugs Isolated CABG without blood Factors associated with bleeding: thinners: • Type of Surgery ~5% Major Bleeding • Surgical duration Re-operation 1/300 • Dura
Slide 12: Brilinta Increases Bleeding Risk in Isolated CABG Surgery
Brilinta Increases Bleeding Risk in Isolated CABG Surgery The European Multicenter Study on CABG (E-CABG) Registry is one of the largest real-world data registries evaluating outcomes in CABG patients – the most common cardiac surgery • In this E-CABG registry study, the incidence of severe or massi
Slide 13: Topline Results of the STAR-T Trial
A Pivotal Randomized, Sham-Controlled Trial Examining the Safety and Efficacy of Intraoperative Removal of Ticagrelor in Patients Undergoing Urgent Cardiac Surgery Topline Results of the STAR-T Trial Michael Mack, MD Richard Whitlock, MD C. Michael Gibson, MD for the STAR-T Investigators April 28, 2
Slide 14: STAR-T RCT: Safe & Timely Antithrombotic Removal of Ticagrelor
STAR-T RCT: Safe & Timely Antithrombotic Removal of Ticagrelor Study Objectives: • Evaluate the safety of intraoperative use of DrugSorb-ATR • Evaluate DrugSorb-ATR efficacy in reducing perioperative bleeding Post-Op Post-Op 140 patients Intraoperative Period Day #1 Day #2 Study Follow-up to Post-Op
Slide 15: STAR-T Results Presented by Dr. Michael Mack
STAR-T Results Presented by Dr. Michael Mack https://ir.cytosorbents.com/events-presentations/ 15 |
Slide 16: STAR-T Key Takeaways & Next Steps
STAR-T Key Takeaways & Next Steps • No safety concerns - Primary safety endpoint met • Imbalances in the number of high-risk non-CABG surgeries and other factors in the treatment arm led to missing the primary efficacy endpoint in overall surgery population (92% CABG + 8% other) • However, the sever
Slide 17: DrugSorb-ATR is a Potential Win for All Stakeholders
DrugSorb-ATR is a Potential Win for All Stakeholders Patients ✓ Minimize delays to definitive surgery ✓ Reduce serious bleeding risk, which is associated with longer hospital stays and increased morbidity and mortality Surgeons ✓ No change in workflow, seamless integration into heart-lung machine ✓
Slide 18: Strong Value Proposition for Hospitals
Strong Value Proposition for Hospitals Waiting in the hospital for multiple days for the drug to “washout” is highly problematic: • Exposes patients to added risk due to the delay of having the needed operation • Increases hospital costs and reduces efficiency by blocking beds and reducing throughpu
Slide 19: US & Canada TAM for Brilinta Removal
US & Canada TAM for Brilinta Removal ~60,000 patients on Brilinta needing emergent/urgent CABG surgery annually in U.S. and Canada x ~ $5,000 per device (USD and Canadian) ~$300M (USD) Initial US & Canada Total Addressable Market Brilinta market share expected to grow • DrugSorb-ATR would make Brili
Slide 20: Large Total Addressable Market
Large Total Addressable Market Future Opportunity $1-2 Billion Near-Term Opportunity >$600M >$200M >$150M >$450M >$450M Initial Opportunity >$300M • U.S. & CAN Ticagrelor Removal in CABG • DOAC Removal in CABG • DOAC Removal in Hospital-Wide Applications • Expansion of U.S. & CAN • U.S. & CAN Ticagr
Slide 21: CytoSorb: Our Core Business
CytoSorb Our Core Business 21 |
Slide 22: CytoSorb Key Facts
CytoSorb Key Facts • E.U. approved and used in 76 countries worldwide with more than a quarter million treatments used cumulatively • By treating deadly inflammation, CytoSorb helps to prevent or treat organ failure – the cause of nearly half of all deaths in the ICU. Because of this, we believe we
Slide 23: CytoSorb Targets Massive Inflammation - the Heart of Critical Illness
CytoSorb Targets Massive Inflammation - the Heart of Critical Illness • Acute inflammation is the body’s mechanism to fight injury and infection • However, severe inflammation, driven by cytokine storm, can cause a chain reaction of problems that can end in organ failure and death CAPILLARY IMMUNE S
Slide 24: Targets Deadly Conditions That Afflict Millions of People
Targets Deadly Conditions That Afflict Millions of People Critical Care Cardiothoracic Surgery Removes the “fuel to the fire” of massive Reduces inflammation and blood thinners, uncontrolled inflammation that is often targeting reduction in complications of cardiac associated with organ failure and
Slide 25: Riding Many Macro Trends in Healthcare
Riding Many Macro Trends in Healthcare Aging Population is Getting Older The Use of Blood Thinners Millions worldwide are on blood thinners to reduce risk of stroke and heart attack >1 billion over 60 Chronic Liver Disease Endocarditis Afflicts 1 in 5 worldwide 25 |
Slide 26: This is Why CytoSorb Continues To Grow in ICU applications
This is Why CytoSorb Continues To Grow in ICU applications Sepsis, Septic Shock, Liver Cytokine storm/ Other Shock Cytokine release Pancreatitis failure syndrome Infectious diseases Post-surgical Neuroinflammation (flu, COVID-19, other) Burn injury complications Organ transplant Acute Respiratory Hi
Slide 27: Financial Performance
27 Financial Performance CytoSorbents.
Slide 28: Annual Product Sales
Annual Product Sales CytoSorbents sells through Direct Sales in 15 countries and Distributors in 60+ others Annual Product Sales 2024: Continued Growth** $45.0 $40.1M • $9.0-9.2M preliminary, unaudited Q4 2024 $39.5M $40.0 product sales, +22-25% growth yoy $6.3 $9.4 $35.4-35.6M** $35.0 • $35.4-35.6M
Slide 29: A Simple and Compelling Value Proposition
A Simple and Compelling Value Proposition • We continue to demonstrate solid top line performance of our core international CytoSorb business in critical care and cardiac surgery • Delivering improved operating efficiencies, margin expansion to drive core business toward cash flow break even in 2H 2
Slide 30: CytoSorbents Corporation
CytoSorbents Corporation NASDAQ: CTSO Company Contact: Dr. Phillip Chan pchan@cytosorbents.com 908-307-0367 www.cytosorbents.com 30